Founded in 2024, Granza Bio is a biotechnology company developing a novel delivery 'shell' platform to direct therapeutic cargo to specific tissues. For their lead candidate, Granza Bio is leveraging the discovery of the immune system's powerful suite of weapons, 'attack particles'. Utilizing their advanced delivery platform, they aim to target these "attack particles" against a range of diseases such as cancer, autoimmune disorders, and infections.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/10/24 | $7,140,000 | Seed |
Felicis Ventures MetaPlanet Holdings North South Ventures Oxford Angel Fund Pioneer Fund Refactor Capital Ritual Capital Y Combinator Zeno Ventures | undisclosed |
